Marina Biotech concludes dosing in START-FAP trial
CEQ508 is intended to be used as a treatment for reducing the levels of beta-catenin protein in the epithelial cells of the small and large intestine. In the
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Luminex’s xTAG GPP detects hemolytic-uremic syndrome (HUS) causing Shiga-like toxin producing E. coli strain (STEC), besides detecting common disease-causing gastrointestinal pathogens, including viruses, bacteria and parasites, such as